Immuneering to Present at the Jefferies Global Healthcare Conference
Rhea-AI Summary
Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company, announced its participation in the upcoming Jefferies Global Healthcare Conference. The event will take place at the Marriott Marquis in New York City from June 4-5, 2025.
The company's management team, including CEO Ben Zeskind, CMO Igor Matushansky, CSO Brett Hall, CBO Harold Brakewood, and CAO Mallory Morales, will deliver a company presentation on June 5 from 8:45-9:15 am ET. The presentation will focus on Immuneering's pipeline, platform, and business strategy. The event will also include one-on-one investor meetings.
A live webcast of the presentation will be available and later archived in the Investor Relations section of Immuneering's website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IMRX declined 5.83%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 4-5, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Brett Hall, Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
Format: Company Presentation and 1x1 Investor Meetings
Date/Time: June 5 from 8:45 – 9:15 am ET
The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Jenna Urban
jurban@cglife.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
When is Immuneering (IMRX) presenting at the Jefferies Global Healthcare Conference 2025?
Who will be representing Immuneering (IMRX) at the Jefferies Healthcare Conference?
Where can I watch Immuneering's (IMRX) presentation at the Jefferies Conference?
What will Immuneering (IMRX) discuss at the Jefferies Healthcare Conference 2025?
